A telomere is a region of repetitive nucleotide sequences at each end of a chromatid, which protects the end of the chromosome from deterioration or from fusion with neighboring chromosomes. Its name is derived from the Greek nouns telos (τέλος) 'end' and merοs (μέρος, root: μερ-) 'part.'
During chromosome replication, the enzymes that duplicate DNA cannot continue their duplication all the way to the end of a chromosome, so in each duplication the end of the chromosome is shortened (this is because the synthesis of Okazaki fragments requires RNA primers attaching ahead on the lagging strand). The telomeres are disposable buffers at the ends of chromosomes which are truncated during cell division; their presence protects the genes before them on the chromosome from being truncated instead.
In 1975–1977, Elizabeth Blackburn, working as a postdoctoral fellow at Yale University with Joseph Gall, discovered the unusual nature of telomeres, with their simple repeated DNA sequences composing chromosome ends. Their work was published in 1978.
Elizabeth Blackburn, Carol Greider, and Jack Szostak were awarded the 2009 Nobel Prize in Physiology or Medicine for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
Nevertheless, in the 1970s there was no recognition that the telomere-shortening mechanism normally limits cells to a fixed number of divisions, or animal studies suggesting that this is responsible for aging on the cellular level and sets a limit on lifespans.
However, in the early 1970s, Russian theorist Alexei Olovnikov first recognized that chromosomes could not completely replicate their ends. Building on this, and to accommodate Leonard Hayflick's idea of limited somatic cell division, Olovnikov suggested that DNA sequences are lost every time a cell/DNA replicates until the loss reaches a critical level, at which point cell division ends.
However, Olovnikov's prediction was not widely known except by a handful of researchers studying cellular aging and immortalization. It remained for a privately funded collaboration from biotechnology company Geron to isolate the genes for the RNA and protein component of human telomerase in order to establish the causal role of telomere shortening in cellular aging and telomerase reactivation in cell immortalization.
Today, it is established that telomeres protect a cell's chromosomes from fusing with each other or rearranging—abnormalities that can lead to cancer—and so cells are destroyed when their telomeres are consumed. Most cancers are the result of "immortal" cells that have ways of evading this programmed senescence.
Nature and function
Structure, function and evolutionary biology
Telomeres are repetitive nucleotide sequences located at the termini of linear chromosomes of most eukaryotic organisms. For vertebrates, the sequence of nucleotides in telomeres is TTAGGG. Most prokaryotes, lacking this linear arrangement, do not have telomeres. Telomeres compensate for incomplete semi-conservative DNA replication at chromosomal ends. A protein complex known as shelterin serves as protection against double-strand break (DSB) repair by homologous recombination (HR) and non-homologous end joining (NHEJ).
In most prokaryotes, chromosomes are circular and, thus, do not have ends to suffer premature replication termination. A small fraction of bacterial chromosomes (such as those in Streptomyces and Borrelia) are linear and possess telomeres, which are very different from those of the eukaryotic chromosomes in structure and functions. The known structures of bacterial telomeres take the form of proteins bound to the ends of linear chromosomes, or hairpin loops of single-stranded DNA at the ends of the linear chromosomes.
While replicating DNA, the eukaryotic DNA replication enzymes (the DNA polymerase protein complex) cannot replicate the sequences present at the ends of the chromosomes (or more precisely the chromatid fibres). Hence, these sequences and the information they carry may get lost. This is the reason telomeres are so important in context of successful cell division: They "cap" the end-sequences and themselves get lost in the process of DNA replication. But the cell has an enzyme called telomerase, which carries out the task of adding repetitive nucleotide sequences to the ends of the DNA. Telomerase, thus, "replenishes" the telomere "cap" of the DNA. In most multicellular eukaryotic organisms, telomerase is active only in germ cells, some types of stem cells such as embryonic stem cells, and certain white blood cells. Telomerase can be re activated and telomeres reset back to an embryonic state by somatic cell nuclear transfer. There are theories that claim that the steady shortening of telomeres with each replication in somatic (body) cells may have a role in senescence and in the prevention of cancer. This is because the telomeres act as a sort of time-delay "fuse", eventually running out after a certain number of cell divisions and resulting in the eventual loss of vital genetic information from the cell's chromosome with future divisions.
Telomere length varies greatly between species, from approximately 300 base pairs in yeast to many kilobases in humans, and usually is composed of arrays of guanine-rich, six- to eight-base-pair-long repeats. Eukaryotic telomeres normally terminate with 3′ single-stranded-DNA overhang, which is essential for telomere maintenance and capping. Multiple proteins binding single- and double-stranded telomere DNA have been identified. These function in both telomere maintenance and capping. Telomeres form large loop structures called telomere loops, or T-loops. Here, the single-stranded DNA curls around in a long circle stabilized by telomere-binding proteins. At the very end of the T-loop, the single-stranded telomere DNA is held onto a region of double-stranded DNA by the telomere strand disrupting the double-helical DNA and base pairing to one of the two strands. This triple-stranded structure is called a displacement loop or D-loop.
Telomere shortening in humans can induce replicative senescence, which blocks cell division. This mechanism appears to prevent genomic instability and development of cancer in human aged cells by limiting the number of cell divisions. However, shortened telomeres impair immune function that might also increase cancer susceptibility. If telomeres become too short, they have the potential to unfold from their presumed closed structure. The cell may detect this uncapping as DNA damage and then either stop growing, enter cellular old age (senescence), or begin programmed cell self-destruction (apoptosis) depending on the cell's genetic background (p53 status). Uncapped telomeres also result in chromosomal fusions. Since this damage cannot be repaired in normal somatic cells, the cell may even go into apoptosis. Many aging-related diseases are linked to shortened telomeres. Organs deteriorate as more and more of their cells die off or enter cellular senescence.
At the very distal end of the telomere is a 300 bp single-stranded portion, which forms the T-Loop. This loop is analogous to a knot, which stabilizes the telomere, preventing the telomere ends from being recognized as break points by the DNA repair machinery. Should non-homologous end joining occur at the telomeric ends, chromosomal fusion will result. The T-loop is held together by seven known proteins, the most notable ones being TRF1, TRF2, POT1, TIN1, and TIN2, collectively referred to as the shelterin complex. The shelterin complex consists of six proteins identified as TRF1, TRF2, TIN2, POT1, TPP1 (also known as TINT1, PTOP, and PIP1), and RAP1.
Cancer, telomerase and ALT (alternative lengthening of telomeres)
||This section may be too technical for most readers to understand. (October 2013)|
Malignant cells that bypass this arrest become immortalized by telomere extension due mostly to the activation of telomerase, the reverse transcriptase enzyme responsible for synthesis of telomeres. Telomerase is a "ribonucleoprotein complex" composed of a protein component and an RNA primer sequence that acts to protect the terminal ends of chromosomes. The actions of telomerase are necessary because, during replication, DNA polymerase can synthesize DNA in only a 5' to 3' direction and can do so only by adding polynucleotides to an RNA primer that has already been placed at various points along the length of the DNA. These RNA strands must later be replaced with DNA. RNA primer replacement is not a problem at origins of replication within the chromosome, because DNA polymerase can use a previous stretch of "upstream" DNA (i.e., located 5' to the RNA template) as a template to backfill the sequence where the RNA primer was. At the chromosome terminal, however, DNA polymerase cannot replace the RNA primer, because there is no position available in the 5' direction to place another RNA primer: nor is there upstream DNA available to use as a primer.
Without telomeres at the end of DNA, this genetic sequence at the chromosomal end would be deleted. The chromosome would grow shorter and shorter in subsequent replications and genetic information would be lost. The telomere prevents this problem by employing a different mechanism to synthesize DNA at the chromosome terminal . This prevents chromosomal fraying and prevents the ends of the chromosome from being processed as a double-strand DNA break, which could lead to chromosome-to-chromosome telomere fusions. Telomeres are extended by telomerases, part of a protein subgroup of specialized reverse transcriptase enzymes known as TERT (TElomerase Reverse Transcriptases). Telomerases are involved in synthesis of telomeres in humans and many other, but not all, organisms. Because of DNA replication mechanisms and oxidative stress, and because TERT expression is very low in many types of human cells, telomeres shrink a little bit every time a cell divides: however, among cell types characterized by extensive cell division, such as stem cells and certain white blood cells, TERT is expressed at higher levels and telomere shortening is partially or fully prevented.
In addition to its TERT protein component, telomerase also contains a piece of template RNA known as the TERC (TElomerase RNA Component) or TR (Telomerase RNA). In humans, this TERC telomere sequence is a repeating string of TTAGGG, between 3 and 20 kilobases in length. There are an additional 100-300 kilobases of telomere-associated repeats between the telomere and the rest of the chromosome. Telomere sequences vary from species to species, but, in general, one strand is rich in G with fewer Cs. These G-rich sequences can form four-stranded structures (G-quadruplexes), with sets of four bases held in plane and then stacked on top of each other, with either a sodium or a potassium ion between the planar quadruplexes.
Mammalian (and other) somatic cells without telomerase gradually lose telomeric sequences as a result of incomplete replication (Counter et al., 1992). As mammalian telomeres shorten, eventually cells reach their replicative limit and progress into senescence or old age. Senescence involves p53 and pRb pathways and leads to the halting of cell proliferation (Campisi, 2005). Senescence may play an important role in suppression of cancer emergence, although inheriting shorter telomeres probably does not protect against cancer. With critically shortened telomeres, further cell proliferation can be achieved by inactivation of p53 and pRb pathways. Cells entering proliferation after inactivation of p53 and pRb pathways undergo crisis. Crisis is characterized by gross chromosomal rearrangements and genome instability, and almost all cells die.
However, 5–10% of human cancers activate the Alternative Lengthening of Telomeres (ALT) pathway, which relies on recombination-mediated elongation. Rarely, cells emerge from crisis immortalized through telomere lengthening by either activated telomerase or ALT (Colgina and Reddel, 1999; Reddel and Bryan, 2003). The first description of an ALT cell line demonstrated that their telomeres are highly heterogeneous in length and predicted a mechanism involving recombination (Murnane et al., 1994). Subsequent studies have confirmed a role for recombination in telomere maintenance by ALT (Dunham et al., 2000), however the exact mechanism of this pathway is yet to be determined. ALT cells produce abundant t-circles, possible products of intratelomeric recombination and t-loop resolution (Tomaska et al., 2000; 2009; Cesare and Griffith, 2004; Wang et al., 2004).
Since shorter telomeres are thought to be a cause of poorer health and aging, this raises the question of why longer telomeres are not selected for to ameliorate these effects. A prominent explanation suggests that inheriting longer telomeres would cause increased cancer rates (e.g. Weinstein and Ciszek, 2002). However, a recent literature review and analysis  suggests this is unlikely, because shorter telomeres and telomerase inactivation is more often associated with increased cancer rates, and the mortality from cancer occurs late in life when the force of natural selection is very low. An alternative explanation to the hypothesis that long telomeres are selected against due to their cancer promoting effects is the "thrifty telomere" hypothesis, which suggests that the cellular proliferation effects of longer telomeres causes increased energy expenditures. In environments of energetic limitation, shorter telomeres might be an energy sparing mechanism.
In healthy female breast, a proportion of cells called luminal progenitors that line the milk ducts have proliferative and differentiation potential and most of them contain critically short telomeres with DNA damage foci. These cells are believed to be the possible common cellular loci where cancers of the breast involving telomere dysregulation may arise. The telomere shortening in these progenitors is not age dependent but is speculated to be basal to luminal epithelial differentiation program-dependent. Also, the telomerase activity are unusually high in these cells when isolated from younger women but decline with age.
|This section does not cite any references or sources. (October 2009)|
Telomeres shorten in part because of the end replication problem that is exhibited during DNA replication in eukaryotes only. Because DNA replication does not begin at either end of the DNA strand, but starts in the center, and considering that all known DNA polymerases move in the 5' to 3' direction, one finds a leading and a lagging strand on the DNA molecule being replicated.
On the leading strand, DNA polymerase can make a complementary DNA strand without any difficulty because it goes from 5' to 3'. However, there is a problem going in the other direction on the lagging strand. To counter this, short sequences of RNA acting as primers attach to the lagging strand a short distance ahead of where the initiation site was. The DNA polymerase can start replication at that point and go to the end of the initiation site. This causes the formation of Okazaki fragments. More RNA primers attach further on the DNA strand and DNA polymerase comes along and continues to make a new DNA strand.
Eventually, the last RNA primer attaches, and DNA polymerase, RNA nuclease, and DNA ligase come along to convert the RNA (of the primers) to DNA and to seal the gaps in between the Okazaki fragments. But, in order to change RNA to DNA, there must be another DNA strand in front of the RNA primer. This happens at all the sites of the lagging strand, but it does not happen at the end where the last RNA primer is attached. Ultimately, that RNA is destroyed by enzymes that degrade any RNA left on the DNA. Thus, a section of the telomere is lost during each cycle of replication at the 5' end of the lagging strand's daughter.
However, in vitro studies have shown that telomeres are highly susceptible to oxidative stress, and Richter and Zglinicki presented evidence that oxidative stress-mediated DNA damage is an important determinant of telomere shortening. Telomere shortening due to free radicals explains the difference between the estimated loss per division because of the end-replication problem (ca. 20 bp) and actual telomere shortening rates (50-100 bp), and has a greater absolute impact on telomere length than shortening caused by the end-replication problem.
Telomere shortening is associated with ageing, mortality and ageing-related diseases. Diminished telomere maintenance is an important precursor to many types of cancers and telomere shortness has been associated with poor clinical outcomes, such as tumor progression and metastasis. Recent research by Ornish et al. has demonstrated increased telomere length and telomerase activity with lifestyle modification.
The phenomenon of limited cellular division was first observed by Leonard Hayflick, and is now referred to as the Hayflick limit. Significant discoveries were subsequently made by a group of scientists organized at Geron Corporation by Geron's founder Michael D. West that tied telomere shortening with the Hayflick limit. This team included Calvin Harley, Bryant Villeponteau, Gregg Morin, William Andrews, Karen Chapman, as well as collaborators at the University of Colorado and the University of Texas Southwestern Medical Center at Dallas. The cloning of the catalytic component of telomerase enabled experiments to test whether the expression of telomerase at levels sufficient to prevent telomere shortening was capable of immortalizing human cells. Telomerase was demonstrated in a 1998 publication in Science to be capable of extending cell lifespan, and now is well-recognized as capable of immortalizing human somatic cells.
It is becoming apparent that reversing shortening of telomeres through temporary activation of telomerase may be a potent means to slow aging. They reason that this would extend human life because it would extend the Hayflick limit. Three routes have been proposed to reverse telomere shortening: drugs, gene therapy, or metabolic suppression, so-called, torpor/hibernation. So far these ideas have not been proven in humans, but it has been demonstrated that telomere shortening is reversed in hibernation and aging is slowed (Turbill, et al. 2012 & 2013) and that hibernation prolongs life-span (Lyman et al. 1981). It has also been demonstrated that telomere extension has successfully reversed some signs of aging in laboratory mice  and the nematode worm species Caenorhabditis elegans. It has been hypothesized that longer telomeres and especially telomerase activation might cause increased cancer (e.g. Weinstein and Ciszek, 2002). However, longer telomeres might also protect against cancer, because short telomeres are associated with cancer. It has also been suggested that longer telomeres might cause increased energy consumption.
Techniques to extend telomeres could be useful for tissue engineering, because they might permit healthy, noncancerous mammalian cells to be cultured in amounts large enough to be engineering materials for biomedical repairs.
That the role of telomeres is far from being understood is demonstrated by two recent studies on long-lived seabirds. In 2003, scientists observed that the telomeres of Leach's Storm-petrel (Oceanodroma leucorhoa) seem to lengthen with chronological age, the first observed instance of such behaviour of telomeres. In 2006, Juola et al. reported that in another unrelated, long-lived seabird species, the Great Frigatebird (Fregata minor), telomere length did decrease until at least c.40 years of age (i.e. probably over the entire lifespan), but the speed of decrease slowed down massively with increasing ages, and that rates of telomere length decrease varied strongly between individual birds. They concluded that in this species (and probably in frigatebirds and their relatives in general), telomere length could not be used to determine a bird's age sufficiently well. Thus, it seems that there is much more variation in the behavior of telomere length than initially believed.
Furthermore, Gomes et al. found, in a study of the comparative biology of mammalian telomeres, that telomere length of different mammalian species correlates inversely, rather than directly, with lifespan, and they concluded that the contribution of telomere length to lifespan remains controversial. Harris et al. found little evidence that, in humans, telomere length is a significant biomarker of normal aging with respect to important cognitive and physical abilities. Gilley and Blackburn tested whether cellular senescence in paramecium is caused by telomere shortening, and found that telomeres were not shortened during senescence.
|Group||Organism||Telomeric repeat (5' to 3' toward the end)|
|Vertebrates||Human, mouse, Xenopus||TTAGGG|
|Filamentous fungi||Neurospora crassa||TTAGGG|
|Slime moulds||Physarum, Didymium||TTAGGG|
|Kinetoplastid protozoa||Trypanosoma, Crithidia||TTAGGG|
|Ciliate protozoa||Tetrahymena, Glaucoma||TTGGGG|
|Oxytricha, Stylonychia, Euplotes||TTTTGGGG|
|Higher plants||Arabidopsis thaliana||TTTAGGG|
|Fission yeasts||Schizosaccharomyces pombe||TTAC(A)(C)G(1-8)|
|Budding yeasts||Saccharomyces cerevisiae||TGTGGGTGTGGTG (from RNA template)
or G(2-3)(TG)(1-6)T (consensus)
|This section requires expansion. (June 2008)|
Studies have found shortened telomeres in many cancers, including pancreatic, bone, prostate, bladder, lung, kidney, and head and neck. In addition, people with many types of cancer have been found to possess shorter leukocyte telomeres than healthy controls.
Cancer cells require a mechanism to maintain their telomeric DNA in order to continue dividing indefinitely (immortalization). A mechanism for telomere elongation or maintenance is one of the key steps in cellular immortalization and can be used as a diagnostic marker in the clinic. Telomerase, the enzyme complex responsible for elongating telomeres, is activated in approximately 90% of tumors. However, a sizeable fraction of cancerous cells employ alternative lengthening of telomeres (ALT), a non-conservative telomere lengthening pathway involving the transfer of telomere tandem repeats between sister-chromatids.
Telomerase is the natural enzyme that promotes telomere repair. It is active in stem cells, germ cells, hair follicles, and 90 percent of cancer cells, but its expression is low or absent in somatic cells. Telomerase functions by adding bases to the ends of the telomeres. Cells with sufficient telomerase activity are considered immortal in the sense that they can divide past the Hayflick limit without entering senescence or apoptosis. For this reason, telomerase is viewed as a potential target for anti-cancer drugs (such as Geron's Imetelstat currently in human clinical trials and telomestatin).
Studies using knockout mice have demonstrated that the role of telomeres in cancer can both be limiting to tumor growth, as well as promote tumorigenesis, depending on the cell type and genomic context.
||This section may be too technical for most readers to understand. (June 2009)|
Several techniques are currently employed to assess average telomere length in eukaryotic cells. The most widely used method is the Terminal Restriction Fragment (TRF) southern blot, which involves hybridization of a radioactive 32P-(TTAGGG)n oligonucleotide probe to Hinf / Rsa I digested genomic DNA embedded on a nylon membrane and subsequently exposed to autoradiographic film or phosphoimager screen. Another histochemical method, termed Q-FISH, involves fluorescent in situ hybridization (FISH). Q-FISH, however, requires significant amounts of genomic DNA (2-20 micrograms) and labor that renders its use limited in large epidemiological studies. Some of these impediments have been overcome with a Real-Time PCR assay for telomere length and Flow-FISH. Real-time PCR assay involves determining the Telomere-to-Single Copy Gene (T/S)ratio, which is demonstrated to be proportional to the average telomere length in a cell.
Another technique, referred to as single telomere elongation length analysis (STELA), was developed in 2003 by Duncan Baird. This technique allows investigations that can target specific telomere ends, which is not possible with TRF analysis. However, due to this technique's being PCR-based, telomeres larger than 25Kb cannot be amplified and there is a bias towards shorter telomeres.
Telomere length is associated with the general health of an individual as well as certain diseases, beyond cancer. While multiple companies offer telomere length measurement services, the utility of these measurements for widespread clinical or personal use has been questioned by prominent scientists without financial interests in these companies. Nobel Prize winner Elizabeth Blackburn, who was the co-founder of one of these companies and has prominently promoted the clinical utility of telomere length measures, resigned from the company in June 2013 "owing to an impending change in the control of Telome Health".
- Biological clock and epigenetic clock
- DNA damage theory of aging
- Maximum life span
- Rejuvenation (aging)
- Senescence, biological aging
- AtGoogleTalks, August 20, 2008 Molecular biologist Elizabeth Blackburn
- Passarge, Eberhard. Color atlas of genetics, 2007.
- Blackburn AM (March 1978). "A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena". J. Mol. Biol. 120 (1): 33–53. doi:10.1016/0022-2836(78)90294-2. PMID 642006.
- "The 2009 Nobel Prize in Physiology or Medicine - Press Release". Nobelprize.org. 2009-10-05. Retrieved 2012-06-12.
- Harrison's Principles of Internal Medicine, Ch. 69, Cancer cell biology and angiogenesis, Robert G. Fenton and Dan L. Longo, p. 454.
- Olovnikov, Alexei M. (1971). "Принцип маргинотомии в матричном синтезе полинуклеотидов" [Principle of marginotomy in template synthesis of polynucleotides]. Doklady Akademii Nauk SSSR (in Russian) 201 (6): 1496–9. PMID 5158754.
- Olovnikov AM (September 1973). "A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon". J. Theor. Biol. 41 (1): 181–90. doi:10.1016/0022-5193(73)90198-7. PMID 4754905.
- "No Nobel physiology and medicine award for Russian gerontologist Aleksey Olovnikov". Telegraph. October 21, 2009.
- "Unravelling the secret of ageing". COSMOS: The Science of Everything. October 5, 2009.
- Blasco, Maria; Paula Martínez (21 JUN 2010). "Role of shelterin in cancer and aging". Aging Cell 9 (5): 653–666. doi:10.1111/j.1474-9726.2010.00596.x. PMID 20569239.
- Lundblad, 2000; Ferreira et al., 2004
- Maloy, Stanley (July 12, 2002). "Bacterial Chromosome Structure". Retrieved 2008-06-22.
- Robert P. Lanza, Jose B. Cibelli, Catherine Blackwell, Vincent J. Cristofalo, Mary Kay Francis, Gabriela M. Baerlocher, Jennifer Mak, Michael Schertzer, Elizabeth A. Chavez, Nancy Sawyer, Peter M. Lansdorp, Michael D. West1 (28 April 2000). "Extension of Cell Life-Span and Telomere Length in Animals Cloned from Senescent Somatic Cells". Science.
- Shampay , Szostak J.W., Blackburn E.H. (1984). "DNA sequences of telomeres maintained in yeast". Nature 310 (5973): 154–157. doi:10.1038/310154a0. PMID 6330571.
- Blackburn, 2001; Smogorzewska and de Lange, 2004; Cech, 2004; De Lange et al., 2005; Kota and Runge, 1999
- Griffith J, Comeau L, Rosenfield S, Stansel R, Bianchi A, Moss H, de Lange T (1999). "Mammalian telomeres end in a large duplex loop". Cell 97 (4): 503–14. doi:10.1016/S0092-8674(00)80760-6. PMID 10338214.
- Burge S, Parkinson G, Hazel P, Todd A, Neidle S (2006). "Quadruplex DNA: sequence, topology and structure". Nucleic Acids Res 34 (19): 5402–15. doi:10.1093/nar/gkl655. PMC 1636468. PMID 17012276.
- Eisenberg DTA (2011). "An evolutionary review of human telomere biology: The thrifty telomere hypothesis and notes on potential adaptive paternal effects". American Journal of Human Biology 23 (2): 149–167. doi:10.1002/ajhb.21127. PMID 21319244.
- Henson JD, Neumann AA, Yeager TR, Reddel RR (2002). Alternative lengthening of telomeres in mammalian cells" Oncogene 21(4) 598-610. Review. PMID 11850785
- BBC, World/Mundo. "Resuelven misterio sobre el origen del cáncer de mama".
- Kannan, Nagarajan; Nazmul Huda, LiRen Tu, Radina Droumeva, Geraldine Aubert, Elizabeth Chavez, Ryan R. Brinkman, Peter Lansdorp, Joanne Emerman, Satoshi Abe, Connie Eaves, David Gilley (4 June 2013). "The Luminal Progenitor Compartment of the Normal Human Mammary Gland Constitutes a Unique Site of Telomere Dysfunction". Stem Cell Reports 1 (1): 28–31. doi:10.1016/j.stemcr.2013.04.003. PMID 24052939.
- Richter T, von Zglinicki T (2007). A continuous correlation between oxidative stress and telomere shortening in fibroblasts. Exp Gerontol 42(11):1039-1042. PMID 17869047
- Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA (2003). Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361:393-395
- Rodier F, Kim SH, Nijjar T, Yaswen P, Campisi J (2005). Cancer and aging: the importance of telomeres in genome maintenance. Int J Biochem Cell Biol 37:977-990
- Ornish D, Lin J, Chan JM, Epel E, Kemp C, Weidner G, Marlin R, Frenda SJ, Magbanua MJ, Daubenmier J, Estay I, Hills NK, Chainani-Wu N, Carroll PR, Blackburn EH (2013). Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet 14(11):1112-20
- Hayflick L, Moorhead PS (1961). "The serial cultivation of human diploid cell strains". Exp Cell Res 25 (3): 585–621. doi:10.1016/0014-4827(61)90192-6. PMID 13905658.
- Hayflick L. (1965). "The limited in vitro lifetime of human diploid cell strains". Exp. Cell Res. 37 (3): 614–636. doi:10.1016/0014-4827(65)90211-9. PMID 14315085.
- Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J (September 1995). "The RNA component of human telomerase". Science 269 (5228): 1236–41. doi:10.1126/science.7544491. PMID 7544491.
- Bodnar, A.G., M. Ouellette, M. Frolkis, S.E. Holt, C.P. Chiu, G.B. Morin, C.B. Harley, J.W. Shay, S. Lichtsteiner, and W.E. Wright. 1998. Extension of life-span by introduction of telomerase into normal human cells" Science 279:349–352. doi:10.1126/science.279.5349.349
- Sample, Ian (November 28, 2010). "Harvard scientists reverse the ageing process in mice – now for humans". The Guardian (London).
- Joeng KS, Song EJ, Lee KJ, Lee J (2004). "Long lifespan in worms with long telomeric DNA". Nature Genetics 36 (6): 607–11. doi:10.1038/ng1356. PMID 15122256.
- Nakagawa S, Gemmell NJ, Burke T (September 2004). "Measuring vertebrate telomeres: applications and limitations". Mol. Ecol. 13 (9): 2523–33. doi:10.1111/j.1365-294X.2004.02291.x. PMID 15315667.
- Juola, Frans A; Haussmann; Dearborn; Vleck (2006). "Telomere shortening in a long-lived marine bird: Cross-sectional analysis and test of an aging tool". The Auk 123 (3): 775. doi:10.1642/0004-8038(2006)123[775:TSIALM]2.0.CO;2. ISSN 0004-8038. More than one of
|last2=specified (help); More than one of
|last3=specified (help); More than one of
- Gomes NM, Ryder OA, Houck ML, Charter SJ, Walker W, Forsyth NR, Austad SN, Venditti C, Pagel M, Shay JW, Wright WE (2011). Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination. Aging Cell 10(5) 761-768. doi: 10.1111/j.1474-9726.2011.00718.x. PMID 21518243
- Harris SE, Martin-Ruiz C, von Zglinicki T, Starr JM, Deary IJ (2010). Telomere length and aging biomarkers in 70-year-olds: the Lothian Birth Cohort 1936. Neurobiol Aging 33(7) 1486.e3-8. PMID 21194798
- Gilley D, Blackburn EH (1994). Lack of telomere shortening during senescence in Paramecium" Proc Natl Acad Sci U S A 91(5) 1955-1958. PMID 8127914
- Willeit Peter, Willeit Johann, Mayr Anita, Weger Siegfried, Oberhollenzer Friedrich, Brandstätter Anita, Kronenberg Florian, Kiechl Stefan (2010). "Telomere length and risk of incident cancer and cancer mortality". JAMA 304 (1): 69–75. doi:10.1001/jama.2010.897. PMID 20606151.
- Henson JD, Neumann AA, Yeager TR, Reddel RR (2002). "Alternative lengthening of telomeres in mammalian cells". Oncogene 21 (4): 598–610. doi:10.1038/sj.onc.1205058. PMID 11850785.
- Chris Molenaar, Karien Wiesmeijer, Nico P. Verwoerd, Shadi Khazen, Roland Eils, Hans J. Tanke, and Roeland W. Dirks (2003-12-15). "Visualizing telomere dynamics in living mammalian cells using PNA probes". The EMBO Journal (The European Molecular Biology Organization) 22 (24): 6631–6641. doi:10.1093/emboj/cdg633. PMC 291828. PMID 14657034.
- Philippi C, Loretz B, Schaefer UF, Lehr CM. (April 2010). "Telomerase as an emerging target to fight cancer - Opportunities and challenges for nanomedicine". Journal of Controlled Releases 146 (2): 228–40. doi:10.1016/j.jconrel.2010.03.025. PMID 20381558.
- Chin L, Artandi SE, Shen Q, et al. (May 1999). "p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis". Cell 97 (4): 527–38. doi:10.1016/S0092-8674(00)80762-X. PMID 10338216.
- Greenberg RA, Chin L, Femino A, et al. (May 1999). "Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse". Cell 97 (4): 515–25. doi:10.1016/S0092-8674(00)80761-8. PMID 10338215.
- Allshire RC et al.; Dempster, M; Hastie, ND (1989). "Human telomeres contain at least three types of G-rich repeat distributed non-randomly". Nucleic Acids Res. 17 (12): 4611–4627. doi:10.1093/nar/17.12.4611. PMC 318019. PMID 2664709.
- Rufer N et al.; Dragowska, W; Thornbury, G; Roosnek, E; Lansdorp, PM (1998). "Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry". Nat Biotechnol 16 (8): 743–747. doi:10.1038/nbt0898-743. PMID 9702772.
- Cawthon, RM (2002). "Telomere measurement by quantitative PCR". Nucleic Acids Research 30 (10): e47. doi:10.1093/nar/30.10.e47. PMC 115301. PMID 12000852.
- Armanios, M; Blackburn, EH (2012). "The telomere syndromes". Nature Reviews Genetics 13 (10): 693–704. doi:10.1038/nrg3246. PMC 3548426. PMID 22965356.
- Codd, V; Nelson, CP; Albrecht, E; Mangino, M; Deelen, J; Buxton, JL; Hottenga, JJ; Fischer, K; Esko, T; Surakka, Ida; Broer, Linda; Nyholt, Dale R; Leach, Irene Mateo; Salo, Perttu; Hägg, Sara; Matthews, Mary K; Palmen, Jutta; Norata, Giuseppe D; O'Reilly, Paul F; Saleheen, Danish; Amin, Najaf; Balmforth, Anthony J; Beekman, Marian; De Boer, Rudolf A; Böhringer, Stefan; Braund, Peter S; Burton, Paul R; Craen, Anton J Mde; Denniff, Matthew; Dong, Yanbin (2013). "Identification of seven loci affecting mean telomere length and their association with disease". Nature Genetics 45 (4): 422–7, 427e1–2. doi:10.1038/ng.2528. PMID 23535734.
- "Telome Health, Inc". Telomehealth.com. Retrieved 2013-07-13.
- "TeloMe Home". Telome.com. Retrieved 2013-07-13.
- "A Blood Test Offers Clues to Longevity".
- Zglinicki, T. v. (13 March 2012). "Will your telomeres tell your future?". BMJ 344 (mar13 1): e1727–e1727. doi:10.1136/bmj.e1727.
- Jo Marchant. "Spit test offers guide to health : Nature News". Nature.com. Retrieved 2013-07-13.
- "Elizabeth Blackburn calls time on 'fountain of youth' firm Telome Health".
- Aubert G., Lansdorp P.M. (April 2008). "Telomeres and Aging". Physiological Reviews 88 (2): 557–579. doi:10.1152/physrev.00026.2007. PMID 18391173
- Cong YS, Wright WE, Shay JW (September 2002). "Human telomerase and its regulation". Microbiol. Mol. Biol. Rev. 66 (3): 407–25, table of contents. doi:10.1128/MMBR.66.3.407-425.2002. PMC 120798. PMID 12208997
- Eisenberg DTA (2011). "An evolutionary review of human telomere biology: The thrifty telomere hypothesis and notes on potential adaptive paternal effects". American Journal of Human Biology 23 (2): n/a–n/a. doi:10.1002/ajhb.21127. PMID 21319244.
- Tomaska L., Nosek J., Kramara J., Griffith J.D. (2009). "Telomeric circles: universal players in telomere maintenance". Nature Structural & Molecular Biology 16 (10): 1010–1015. doi:10.1038/nsmb.1660. PMID 19809492.
- Weinstein BS, Ciszek D (May 2002). "The reserve-capacity hypothesis: evolutionary origins and modern implications of the trade-off between tumor-suppression and tissue-repair". Exp. Gerontol. 37 (5): 615–27. doi:10.1016/S0531-5565(02)00012-8. PMID 11909679 — A paper detailing the evolutionary origins and medical implications of the vertebrate telomere system, including the pervasive trade-off between cancer prevention and damage repair. Also addresses the probable danger posed by the elongation of telomeres in lab mice.
- Elizabeth Blackburn's seminars: "Telomeres and Telomerase"
- Telomeres and Telomerase: The Means to the End Nobel Lecture by Elizabeth Blackburn, which includes a reference to the impact of stress, and pessimism on telomere length
- Telomerase and the Consequences of Telomere Dysfunction Nobel Lecture by Carol Greider
- DNA Ends: Just the Beginning Nobel Lecture by Jack Szostak